期刊
JOURNAL OF CANCER PREVENTION
卷 26, 期 1, 页码 71-82出版社
KOREAN SOC CANCER PREVENTION
DOI: 10.15430/JCP.2021.26.1.71
关键词
Chemoprevention; Immunoprevention; Cancer vaccines; Clinical trials as topic
类别
资金
- NCI [R01 CA235677, HHSN261201500018I, 75N91019D00021, R01CA217161, HHSN261201500018I/HHSN26100004, RO1CA090890, RO1CA122959, P30CA016672, N01CN2015000037, R01CA223804, R35CA197222, HHFN 2612201200035I/HHSN26100003, R01CA226690]
- NIH [R01CA137178, R01CA202704, R35CA253185, U19AG062682, DP5OD021353, U01CA233097]
- John S. Dunn Foundation
- Texas AM University
- Burroughs Wellcome Fund
- Breast Cancer Alliance
- ESSCO MGH Breast Cancer Research Fund
- American Cancer Society
- Breast Cancer Research Foundation [BCRF-19-096]
- Michigan Economic Development Fund [MiTRAC Subk00010972]
- The NCI [U01CA233056, R01CA211611, R01CA227273, N01CN250026, R01CA213987, P30CA06973, P50CA098252, R01CA233486, R01CA237067, R01CA193835, R41CA199956, F31CA213982, R01CA219463, P30 CA016672, HHSN2612015000371/HHSN26100005, 75N91019D00020/75N91019F00130]
- Kentucky Science and Technology Corporation [KSTC-184-512-16-237]
- Masonic Cancer Center
- State of Minnesota Eagles
- University of Minnesota Foundation: the Drug Development Program
- Frederick and Alice Stark Endowment
The meeting aimed to facilitate exchanges in cancer prevention research, highlight new trends in immunoprevention and chemoprevention, provide NCI resources to the research community, and cover various stages from basic research to clinical trials.
The Division of Cancer Prevention of the National Cancer Institute (NCI) and the Office of Disease Prevention of the National Institutes of Health co-sponsored the Translational Advances in Cancer Prevention Agent Development Meeting on August 27 to 28, 2020. The goals of this meeting were to foster the exchange of ideas and stimulate new collaborative interactions among leading cancer prevention researchers from basic and clinical research; highlight new and emerging trends in immunoprevention and chemoprevention as well as new information from clinical trials; and provide information to the extramural research community on the significant resources available from the NCI to promote prevention agent development and rapid translation to clinical trials. The meeting included two plenary talks and five sessions covering the range from pre-clinical studies with chemo/immunopreventive agents to ongoing cancer prevention clinical trials. In addition, two NCI informational sessions describing contract resources for the preclinical agent development and cooperative grants for the Cancer Prevention Clinical Trials Network were also presented.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据